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Abstract The release of two mitochondrial proteins, cyto-
chrome c and apoptosis-inducing factor (AIF), into the soluble
cytoplasm of cells undergoing apoptosis is well established. Using
spectrophotometric determination of enzyme activity, the accu-
mulation of adenylate kinase (AK) activity in the cytosolic
fraction of apoptotic cells has also been observed recently.
However, three isozymes, AK1, AK2 and AK3, have been
characterized in mammalian cells and shown to be localized in
the cytosol, mitochondrial intermembrane space and mitochon-
drial matrix, respectively, and it is unknown which one of these
isozymes accumulates in the cytosol during apoptosis. We now
demonstrate that in apoptotic cells only AK2 was translocated
into the cytosol concomitantly with cytochrome c. The amount of
AK1 in cytosol, as well as the amount of matrix-associated AK3,
remained unchanged during the apoptotic process. Thus, our data
suggest that only intermembrane proteins are released from
mitochondria during the early phase of the apoptotic process.
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1. Introduction
Apoptosis is a mode of cell death, which is characterized by
distinct morphological changes, including cell shrinkage, plas-
ma and nuclear membrane blebbing, organelle compaction,
condensation of chromatin and production of membrane-en-
closed particles containing intracellular material known as
‘apoptotic bodies’. Recently it has become clear that the mi-
tochondria play a critical role in the early phase of apoptosis
(for review see [1]). Thus, it is now well established that at
least two proteins, cytochrome c and apoptosis-inducing fac-
tor (AIF), are released from mitochondria of apoptotic cells.
AIF is a V50 kDa protein, which can induce apoptotic
changes in isolated nuclei [2]. Cytochrome c is a component
of the cytoplasmic ‘apoptosome’ complex, which binds to
Apaf-1; in the presence of dATP this binding leads to the
sequential activation of pro-caspase-9 and other downstream
caspases [3]. The mechanism of cytochrome c release is still
unknown, although three di¡erent hypotheses have been pro-
posed: (a) cytochrome c is released via speci¢c channels in the
outer mitochondrial membrane, which are opened by certain
members of the Bcl-2-family of proteins, such as Bid, Bad or
Bax [4]; (b) the opening of mitochondrial permeability tran-
sition pores, which results in the reduction of the mitochon-
drial transmembrane potential (v8m), is responsible for cyto-
chrome c release [2]; (c) leakage of cytochrome c occurs as a
result of mitochondrial swelling and rupture of the outer
membrane independently of loss of v8m [5].
Recently, using spectrophotometric determination of en-
zyme activity, adenylate kinase (AK) has been reported to
accumulate in the cytosolic fraction of apoptotic cells con-
comitantly with the release of cytochrome c [6]. Adenylate
kinase is a ubiquitous enzyme that contributes to the regula-
tion of the homeostasis of the cellular adenine and guanine
nucleotide pools. Three isozymes, AK1, AK2 and AK3, have
been characterized to date [7]. All three AKs are nuclear-en-
coded proteins and synthesized in the cytoplasm. AK1 re-
mains located mainly in the cytosol of di¡erent tissues. Ma-
ture AK2 and AK3, however, are imported into
mitochondria, where they are sorted to di¡erent submitochon-
drial locations; AK2 is present in the intermembrane space
whereas AK3 is located exclusively in the mitochondrial ma-
trix and uses GTP instead of ATP as a phosphate donor [7]. It
is unknown which one of the adenylate kinase isoforms accu-
mulates in the soluble cytoplasm during apoptosis. In this
study we demonstrate that in apoptotic cells AK2 was trans-
located into the cytosol concomitantly with cytochrome c. The
amount of AK1 in cytosol remained unaltered as did the
amount of the matrix-associated AK3. Thus, our data suggest
that only intermembrane space proteins are released from
mitochondria during the early phase of the apoptotic process.
2. Materials and methods
2.1. Cell culture and induction of apoptosis
Jurkat cells (human leukemic T cell line) were grown in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf serum,
2 mM glutamine, 100 units/ml penicillin, and 100 Wg/ml streptomycin
in a humidi¢ed atmosphere of 5% CO2 in air at 37‡C. The cells were
maintained in a logarithmic growth phase by routine passage every
3^4 days. Apoptosis was induced in cells by treatment with etoposide
(6 Wg/ml).
2.2. Immunoblot analysis
Untreated cells and cells treated with etoposide were washed twice
in ice-cold PBS, resuspended in S-100 bu¡er (20 mM HEPES, pH 7.5,
10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA), supple-
mented with protease inhibitors (0.1 mM PMSF, 10 mg/ml leupeptin,
5 mg/ml pepstatin A, 2 mg/ml aprotinin, 25 mg/ml calpain I inhibitor,
1 mM DTT), and incubated on ice for 10 min. Cells were centrifuged
at 10 000Ug for 15 min at 4‡C. The supernatant was then subjected to
centrifugation at 100 000Ug for 1 h. For analysis of release of mito-
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chondrial proteins, 100 Wl of post-mitochondrial cytoplasmic extract
(10 000Ug supernatant) as well as mitochondrial pellets were mixed
with 5 times concentrated Laemmli’s loading bu¡er, boiled for 4 min
and subjected to 12% SDS-PAGE at 130 V followed by electroblot-
ting to nitrocellulose (0.2 Wm) for 2 h at 100 V. Membranes were
blocked overnight in a bu¡er (50 mM Tris, pH 7.5, 500 mM NaCl)
containing 1% bovine serum albumin and 5% non-fat dried milk.
Then they were sequentially probed with the anti-cytochrome c
(1:2500), anti-AK1, AK2 and AK3 (all at 1:2000) antibodies, fol-
lowed by 1 h incubation with secondary IgG (1:10 000), and then
visualized by ECL according to manufacturer’s instructions.
3. Results and discussion
Although the release of cytochrome c from mitochondria
has been observed in di¡erent experimental models of apop-
tosis, the kinetics of this release are not identical in every
system [8]. Therefore we ¢rst examined cytochrome c release
in our experimental system. Mitochondrial and cytosolic frac-
tions were isolated at di¡erent time points from Jurkat cells
incubated with etoposide, and equal amounts of protein were
subjected to SDS-PAGE. Immunoblot analysis revealed eto-
poside-induced release of cytochrome c from mitochondria
and its accumulation in the cytosol within 1^2 h of incubation
(Fig. 1). Accumulation of a considerable amount of mitochon-
drial cytochrome c in the cytosolic fraction was observed at
4^5 h of incubation (Fig. 1). At 6 h, only small amounts of
cytochrome c remained in the mitochondrial fraction of eto-
poside-treated cells. Activation of caspase-3-like proteases,
measured by cleavage of a £uorogenic substrate (DEVD-
AMC), was initially detected at 3 h after treatment, whereas
DNA fragmentation was observed at 5 h (data not shown).
Thus, in etoposide-treated Jurkat cells, cytochrome c release
preceded the activation of class II caspases (DEVD-ases).
To address the question of which AK isozyme is responsible
for the increase in adenylate kinase activity in the cytosolic
fraction of apoptotic cells [6], the same membranes were
probed with antiserum against di¡erent adenylate kinases.
As described above, AK1 is present mainly in soluble cyto-
plasm of di¡erent tissues, such as skeletal muscle, brain and
erythrocytes. In agreement with these observations, a faint
band of AK1 was found in the cytosol of Jurkat cells, whereas
no AK1 protein was present in the mitochondrial fraction
(Fig. 1). The amount of AK1 in the cytosol did not change
markedly during 6 h of incubation with etoposide. These re-
sults suggested that the increased AK activity in the cytosol of
apoptotic cells was not coupled to an increased amount of
AK1.
Another isoform of adenylate kinase, AK2, exists in the
mitochondrial intermembrane space of many cell types. Small
amounts of this protein can also be found in the cytosol of
liver cells [7]. The low AK activity in the cytosol of di¡erent
cell types [6] could thus be dependent not only on the presence
of AK1, but also on the presence of trace amounts of AK2
[7]. However, using speci¢c antiserum, AK2 was found only in
the mitochondrial fraction of untreated Jurkat cells (Fig. 1).
After treatment with etoposide, accumulation of AK2 in the
cytosolic fraction occurred simultaneously with the accumula-
tion of cytochrome c (Fig. 1). At 6 h of incubation only trace
amounts of AK2 remained in the mitochondrial fraction.
As mentioned above, AK3 is localized mainly in the matrix
of mitochondria. Western blot analysis using antiserum
against AK3, revealed two bands with a molecular weight
of 26 and 25 kDa, respectively, in the mitochondrial fraction
of Jurkat cells (Fig. 1), which is in agreement with previously
published results [7]. No AK3 was observed in the cytosolic
fraction. Moreover, the amount of mitochondrial AK3 was
stable during the time of investigation, suggesting that it was
not released from the mitochondrial matrix.
Thus, the above experiments have shown that two proteins
located in the mitochondrial intermembrane space, cyto-
chrome c and AK2, are released concomitantly in etoposide-
treated Jurkat cells. The release of both enzymes seems to be a
general phenomenon in apoptosis, since it was also observed
in Jurkat cells treated with agonistic anti-CD95 antibodies,
staurosporine, or multimeric K-lactalbumin (data not shown).
The mechanism for the release of cytochrome c and AK2, as
well as AIF, from mitochondria in cells undergoing apoptosis
is still unclear. As mentioned above, several possible pathways
for the release of mitochondrial constituents have been sug-
gested [1]. Recently it has been reported that this release oc-
curs prior to mitochondrial ultracondensation, formation of
outer membrane discontinuities and loss of electrical potential
across the inner mitochondrial membrane [9], which would be
in agreement with early work suggesting that mitochondria
are structurally intact during the initiation stage of the apop-
totic cascade [10]. The importance of rupture of the outer
mitochondrial membrane and dissipation of v8m for the leak-
age of mitochondrial constituents is still unknown. Some
blood cells can survive and maintain clonogenicity with re-
duced mitochondrial membrane potential [11]. It is also pos-
sible that the order of cytochrome c release, functional
changes in mitochondrial membranes and commitment to
apoptosis can vary between cell types and apoptotic stimuli
[11].
As mentioned above, cytochrome c released into the soluble
cytoplasm functions as a component of the ‘apoptosome’
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Fig. 1. Time-course of cytochrome c and adenylate kinase release in
etoposide-treated cells. The 10 000Ug supernatants and pellets from
etoposide-treated cells were prepared for Western blotting. The
membranes were probed with antiserum against cytochrome c, ad-
enylate kinase 1 (AK1), adenylate kinase 2 (AK2) or adenylate ki-
nase 3 (AK3).
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complex. Its ability to do so is based on stringent allosteric
interactions between cytochrome c and other cytoplasmic fac-
tors, including dATP, and does not depend on redox reactions
of cytochrome c [12]. The function of adenylate kinases in
normal cells is restricted to the phosphorylation of AMP to
ADP, which is further phosphorylated to ATP either by gly-
colytic enzymes or through oxidative phosphorylation. The
functional role for AK during the apoptotic process is un-
known. It can be speculated, however, that AK, once released
from mitochondria, may a¡ect the levels of ADP and ATP or
dATP, in conjunction with ribonucleotide reductase, and
thereby contribute to the apoptotic process via the ‘apopto-
some’ complex. It could also be that a possible role for AK in
the apoptotic process does not relate to the ‘normal function’
of AK in cells. Interestingly, a new adenylate kinase, AK4,
was recently isolated from brain and shown to act speci¢cally
on energy metabolism rather than in the control of homeo-
stasis of the ADP pool [13]. Investigation of the role of AKs
in apoptosis is part of ongoing research in our laboratory.
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